Sponsor or institution

Clinical trials and research at National Cancer Institute (NCI)

• 137Clinical trials
• 9Countries

Newest trials

All recruiting trials (137)

• Glofitamab with R-CHOP for Newly Diagnosed HIV-Related Large B-Cell Lymphoma

  This phase 1 study tests glofitamab plus R-CHOP chemoimmunotherapy in adults newly diagnosed with HIV-related large B-cell lymphoma to see if the regimen is safe and tolerable.

  Recruiting Phase 1 National Cancer Institute (NCI) · Rockville, Maryland · NCT07649304

• Combo therapy with selumetinib and trastuzumab deruxtecan for advanced pancreatic cancer

  This phase 1/2 trial tests whether the combination of selumetinib and DS-8201a (trastuzumab deruxtecan) is safe and whether it can help people with unresectable or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Pittsburgh, Pennsylvania · NCT07619521

• Quadruplet induction plus autologous transplant followed by teclistamab maintenance for plasma cell leukemia

  This phase 2 trial tests whether adding teclistamab as consolidation after autologous stem cell transplant improves overall survival for patients with plasma cell leukemia compared with the standard D-KRd consolidation.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · La Jolla, California and 10 other locations · NCT07605416

• Combining botensilimab and balstilimab after standard treatment for colorectal cancer

  This phase 2 trial tests whether giving botensilimab and balstilimab after standard therapy can clear detectable ctDNA in adults with stage II/III colorectal cancer.

  Recruiting at 2 sites Phase 2 National Cancer Institute (NCI) · New Orleans, Louisiana and 1 other locations · NCT07551596

• Neoadjuvant immunotherapy with botensilimab and balstilimab for high-risk non-metastatic clear cell RCC

  This trial tests whether giving botensilimab and balstilimab before kidney tumor surgery is safe and helps patients with high‑risk non‑metastatic clear cell RCC proceed to nephrectomy.

  Recruiting at 5 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 4 other locations · NCT07516366

• Sacituzumab govitecan with bevacizumab vs standard chemotherapy for recurrent platinum-sensitive ovarian cancer after PARP inhibitor maintenance

  This phase II study tests whether sacituzumab govitecan plus bevacizumab can help people with recurrent platinum-sensitive ovarian cancer, after PARP inhibitor maintenance, more than the usual carboplatin, PLD, and bevacizumab treatment.

  Recruiting at 23 sites Phase 2 National Cancer Institute (NCI) · Fayetteville, Arkansas and 22 other locations · NCT07504588

• Teclistamab plus pomalidomide vs standard therapy for relapsed multiple myeloma

  This study tests whether the combination of teclistamab and pomalidomide can work better than the usual regimen (carfilzomib, pomalidomide, and dexamethasone) for adults whose multiple myeloma has returned after some improvement.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Duarte, California · NCT07463807

• Iberdomide added to chemoimmunotherapy for relapsed or refractory neuroblastoma

  This study tests whether adding iberdomide to a chemoimmunotherapy regimen helps children and young people with relapsed, refractory, or progressing neuroblastoma.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Oakland, California and 3 other locations · NCT07437963

• See if shorter venetoclax treatment plus ASTX727 works as well as longer use in older adults with newly diagnosed AML

  This trial tests whether giving venetoclax for 14 days per cycle with ASTX727 is as effective as 28 days per cycle for older adults newly diagnosed with AML.

  Recruiting at 64 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 63 other locations · NCT07437950

• Hormone therapy with ribociclib vs chemotherapy followed by hormone therapy with ribociclib for high-risk stage breast cancer

  This trial tests whether hormone therapy with ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for patients with high-stage, estrogen receptor-positive, HER2-negative breast cancer at low risk of recurrence.

  Recruiting at 257 sites Phase 3 National Cancer Institute (NCI) · Jonesboro, Arkansas and 257 other locations · NCT07391774

• Atezolizumab after surgery to prevent NSCLC from coming back

  This trial tests whether giving atezolizumab (with or without hyaluronidase) for one year after complete surgery helps prevent NSCLC from returning compared with observation.

  Recruiting at 145 sites Phase 3 National Cancer Institute (NCI) · Anaheim, California and 144 other locations · NCT07388524

• Teclistamab for recurrent or refractory plasmablastic lymphoma

  This early-phase trial tests a bispecific antibody called teclistamab to see if it is safe and usable at different doses for adults whose plasmablastic lymphoma has returned or not responded to previous treatment.

  Recruiting at 20 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 19 other locations · NCT07332507

• Self-collected HPV testing to help prevent cervical cancer

  This trial tests whether people referred for colposcopy can collect their own vaginal sample for HPV testing and whether those self-samples match clinician-collected cervical samples.

  Recruiting at 18 sites National Cancer Institute (NCI) · Birmingham, Alabama and 17 other locations · NCT07281430

• Adding cemiplimab to chemotherapy before surgery for sinonasal squamous cell carcinoma

  This test checks whether adding the immunotherapy cemiplimab to carboplatin and paclitaxel before surgery helps people with locally advanced sinonasal squamous cell carcinoma.

  Recruiting at 18 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 17 other locations · NCT07281417

• Adding bevacizumab to carboplatin, paclitaxel and pembrolizumab for pMMR, TP53‑mutated advanced or recurrent endometrial cancer

  This trial tests whether adding bevacizumab to carboplatin and paclitaxel with pembrolizumab helps people with pMMR, TP53‑mutated advanced or recurrent endometrial cancer live longer without the disease getting worse.

  Recruiting at 308 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 308 other locations · NCT07198074

• Adding chemotherapy or chemo-immunotherapy to standard salvage surgery for advanced head and neck cancer

  This trial tests whether giving chemotherapy alone or chemotherapy plus the immunotherapy cemiplimab before salvage surgery helps people with PD-L1–positive recurrent or persistent head and neck squamous cell carcinoma.

  Recruiting at 114 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT07195734

• Camonsertib added to precise radiation therapy for recurrent head and neck cancer

  This early-phase study tests whether the cancer drug camonsertib, given with targeted SBRT radiation, is safe and tolerable for people with recurrent or unresectable head and neck squamous cell carcinoma.

  Recruiting at 4 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 3 other locations · NCT07156227

• Pidnarulex plus cemiplimab for refractory microsatellite-stable colorectal cancer.

  This tests whether combining pidnarulex with cemiplimab is safe and can help people whose microsatellite-stable colorectal cancer has stopped responding to standard treatments.

  Recruiting at 7 sites Phase 1/2 National Cancer Institute (NCI) · Aurora, Colorado and 6 other locations · NCT07147231

• Safety of combining pidnarulex (CX-5461) with trastuzumab deruxtecan for HER2-positive, HER2-low/ultralow breast and other HER2-expressing solid tumors

  This trial tests whether adding pidnarulex to trastuzumab deruxtecan is safe and finds the best dose for adults with HER2-positive, HER2-low/ultralow, or other HER2-expressing advanced or metastatic breast and solid tumors.

  Recruiting at 2 sites Phase 1 National Cancer Institute (NCI) · Boston, Massachusetts and 1 other locations · NCT07137416

• CX-5461 (Pidnarulex) for aggressive B‑cell lymphomas with MYC gene changes

  This trial tests whether the IV drug CX-5461 (Pidnarulex) is safe and can shrink or control aggressive B‑cell lymphomas that have MYC gene changes in adults who have already had other treatments.

  Recruiting at 8 sites Phase 1/2 National Cancer Institute (NCI) · Irvine, California and 7 other locations · NCT07069699

• Induction pembrolizumab with carboplatin/paclitaxel before chemoradiation and pembrolizumab maintenance for high‑risk locally advanced cervical cancer

  This phase III trial tests whether giving pembrolizumab with carboplatin and paclitaxel before chemoradiation, then continuing pembrolizumab as maintenance, helps people with locally advanced high‑risk cervical cancer stay free of progression longer than starting pembrolizumab during chemoradiation.

  Recruiting at 340 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 346 other locations · NCT07061977

• Immunotherapy plus radiation to avoid bladder removal after chemo for muscle-invasive bladder cancer

  This phase II test gives pembrolizumab with radiation after chemotherapy to try to help people with muscle-invasive bladder cancer keep their bladders instead of having them removed.

  Recruiting at 171 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 181 other locations · NCT07061964

• Mirdametinib for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

  This phase II trial tests whether the oral MEK inhibitor mirdametinib can shrink or control relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults.

  Recruiting at 9 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 8 other locations · NCT07061951

• Amivantamab plus hyaluronidase versus cetuximab for advanced cutaneous squamous cell carcinoma in people with weakened immune systems

  This phase II trial tests whether amivantamab with hyaluronidase works better than cetuximab for people with recurrent or metastatic cutaneous squamous cell carcinoma who have a weakened immune system.

  Recruiting at 59 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 58 other locations · NCT07042295

• Cedazuridine/decitabine with filgrastim dose escalation after stem cell transplant for children with high-risk AML

  This phase 1 trial will test whether giving the oral combination cedazuridine/decitabine (ASTX727) together with filgrastim is safe and find the highest tolerable dose for children with high-risk acute myeloid leukemia after allogeneic stem cell transplant.

  Recruiting at 14 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 14 other locations · NCT07012044

• Combining sotorasib and trastuzumab deruxtecan for advanced KRAS G12C non-small cell lung cancer

  This trial tests whether giving sotorasib with trastuzumab deruxtecan is safe and can shrink tumors or slow progression in people with locally advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation and progressed after prior targeted therapy, immunotherapy, and chemotherapy.

  Recruiting at 9 sites Phase 1/2 National Cancer Institute (NCI) · Sacramento, California and 8 other locations · NCT07012031

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• Vanguard: a new blood test approach to screen for multiple cancers

  This study will test two different blood-based multi-cancer detection tests in adults 45–75 without cancer to see if they find cancers earlier than usual care.

  Recruiting at 46 sites National Cancer Institute (NCI) · Pleasanton, California and 45 other locations · NCT06995898

• Cemiplimab with or without CDX-1140 given before surgery for stage III-IV head and neck cancer

  This trial tests whether adding the immune stimulant CDX-1140 to cemiplimab before surgery helps shrink tumors in people with resectable stage III-IV head and neck squamous cell carcinoma.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 11 other locations · NCT06980038

• Tovorafenib plus rituximab for classical hairy cell leukemia

  This trial tests whether combining tovorafenib and rituximab is safe and effective for adults with relapsed or refractory classical hairy cell leukemia and compares that combination to cladribine plus rituximab in newly diagnosed patients.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Bethesda, Maryland and 3 other locations · NCT06965114

• Daratumumab‑hyaluronidase plus teclistamab vs standard daratumumab combinations for high‑risk relapsed or refractory multiple myeloma

  This phase 2 trial tests whether combining daratumumab with teclistamab helps people with high‑risk myeloma that has not responded to treatment or has come back, compared to usual daratumumab‑based therapies.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 31 other locations · NCT06948084

• Venetoclax or GO added to standard chemotherapy for CBF-AML

  This phase 2 trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual cytarabine/daunorubicin regimen helps people with core-binding factor AML achieve higher complete remissions without residual disease.

  Recruiting at 81 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 80 other locations · NCT06917911

• Adding cabozantinib to cemiplimab for adolescents and adults with advanced adrenocortical cancer

  This test sees if adding the targeted drug cabozantinib to the immunotherapy cemiplimab helps adolescents and adults with advanced, unresectable, recurrent, or metastatic adrenocortical cancer.

  Recruiting at 80 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 80 other locations · NCT06900595

• Adding triapine to radiation therapy for recurrent glioblastoma and astrocytoma

  This early-phase study tests whether giving the drug triapine together with radiation is safe and tolerable for adults whose glioblastoma or astrocytoma has come back.

  Recruiting at 36 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06860594

• Sapanisertib plus cabozantinib for metastatic liver cancer with beta-catenin changes

  This trial tests whether adding sapanisertib to cabozantinib helps people with metastatic liver cancer that has a beta-catenin gene change.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Irvine, California and 3 other locations · NCT06811116

• Combining pembrolizumab with radiation therapy for bladder cancer treatment

  This study is testing if combining the immunotherapy drug pembrolizumab with radiation therapy can help people with non-muscle invasive bladder cancer do better than standard chemotherapy during treatment.

  Recruiting at 135 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 146 other locations · NCT06770582

• Itraconazole with endoscopic ablation to prevent esophageal cancer in high‑risk Barrett's esophagus

  This study tests if adding itraconazole to the standard endoscopic ablation can better prevent esophageal cancer in people with high-risk Barrett's esophagus.

  Recruiting at 4 sites Phase 2 National Cancer Institute (NCI) · Kansas City, Kansas and 5 other locations · NCT06732388

• Combining CA-4948 with chemotherapy for metastatic colorectal cancer

  This study is testing a new drug called CA-4948 combined with chemotherapy to see if it can safely help people with metastatic colorectal cancer.

  Recruiting at 13 sites Phase 1 National Cancer Institute (NCI) · Gainesville, Florida and 12 other locations · NCT06696768

• New treatment options for acute myeloid leukemia with IDH2 gene changes

  This study is testing a new combination of treatments for older patients or younger patients who can't take standard therapy and have newly diagnosed acute myeloid leukemia with an IDH2 gene change to see if it helps them achieve better remission rates.

  Recruiting at 127 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 137 other locations · NCT06672146

• Comparing ASTX727 with and without Iadademstat for advanced blood cancers

  This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 31 other locations · NCT06661915

• Combining Abemaciclib with 5-Fluorouracil for Advanced Colorectal Cancer

  This study is testing if a new combination of the cancer drug abemaciclib and the standard chemotherapy drug 5-fluorouracil can help people with advanced colorectal cancer feel better and improve their treatment outcomes.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Irvine, California and 7 other locations · NCT06654037

• ViPOR combination therapy for relapsed or refractory aggressive B‑cell lymphoma

  This treatment will try a five‑drug targeted combination called ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in adults whose aggressive B‑cell lymphoma has relapsed or not responded to prior therapy, focusing on specific genetic subtypes like CD10‑negative DLBCL and high‑grade B‑cell lympho

  Recruiting at 99 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT06649812

• Testing the drug CX-5461 in patients with metastatic solid cancers

  This study is testing a new drug called CX-5461 in patients with advanced solid cancers to see if it can help shrink tumors and how safe it is to use.

  Recruiting Phase 1 National Cancer Institute (NCI) · Bethesda, Maryland · NCT06606990

• Combining cetuximab with pembrolizumab for advanced head and neck cancer

  This study is testing if adding cetuximab to pembrolizumab can help people with advanced head and neck cancer live longer and feel better compared to just using pembrolizumab alone.

  Recruiting at 192 sites Phase 3 National Cancer Institute (NCI) · Little Rock, Arkansas and 201 other locations · NCT06589804

• Combining Enasidenib with Standard Treatment for Higher-Risk Myelodysplastic Syndrome

  This study is testing if adding a new drug called enasidenib to standard treatment can help people with higher-risk myelodysplastic syndrome and an IDH2 mutation achieve better remission rates.

  Recruiting at 147 sites Phase 2 National Cancer Institute (NCI) · Berkeley, California and 150 other locations · NCT06577441

• TPST-1495 treatment for people with familial adenomatous polyposis

  This trial will try an oral drug called TPST-1495 to see if it reduces the number of polyps in the small bowel and colon in people with familial adenomatous polyposis.

  Recruiting at 2 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 3 other locations · NCT06557733

• Pembrolizumab plus sacituzumab govitecan versus standard treatments for advanced urothelial cancer

  This trial will test whether adding sacituzumab govitecan to pembrolizumab works better than standard chemotherapy options for adults with locally advanced or metastatic urothelial cancer who have progressed after prior therapy.

  Recruiting at 161 sites Phase 3 National Cancer Institute (NCI) · Phoenix, Arizona and 162 other locations · NCT06524544

• Adding abemaciclib to gemcitabine chemotherapy for advanced soft tissue sarcoma

  This phase 1/2 trial tests whether adding the targeted drug abemaciclib to gemcitabine is safe and works better than gemcitabine plus docetaxel for adults with advanced or metastatic leiomyosarcoma or dedifferentiated liposarcoma whose tumors are Rb-positive.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Houston, Texas · NCT06498648

• Immunotherapy after surgery for early-stage non-small cell lung cancer

  This study is testing if the immunotherapy drug durvalumab can help people with early-stage non-small cell lung cancer stay cancer-free longer after surgery compared to just keeping an eye on them.

  Recruiting at 279 sites Phase 3 National Cancer Institute (NCI) · Jonesboro, Arkansas and 283 other locations · NCT06498635

• Testing a new anti-cancer drug for patients with acute myeloid leukemia and myelodysplastic syndromes

  This study is testing a new anti-cancer drug called cirtuvivint, alone and with another drug, to see if it helps people with acute myeloid leukemia and myelodysplastic syndromes feel better and live longer.

  Recruiting at 20 sites Phase 1 National Cancer Institute (NCI) · New Haven, Connecticut and 22 other locations · NCT06484062

• Testing a new combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of two treatments, iberdomide and teclistamab, to see if they can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Phoenix, Arizona and 16 other locations · NCT06465316

• Combining pembrolizumab and CA-4948 for advanced urothelial cancer treatment

  This study is testing a new combination of two drugs, pembrolizumab and CA-4948, to see if it can help people with advanced urothelial cancer that hasn't responded to other treatments.

  Recruiting at 11 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT06439836

• Combining immunotherapy with chemotherapy for aggressive sarcomas

  This study is testing if combining immunotherapy with chemotherapy can help people with aggressive sarcomas live longer and feel better compared to just using chemotherapy alone.

  Recruiting at 247 sites Phase 3 National Cancer Institute (NCI) · Phoenix, Arizona and 268 other locations · NCT06422806

• Combining two anticancer drugs for treating advanced gastric and gastroesophageal junction cancers

  This study is testing a new combination of two cancer drugs to see if they can help people with advanced HER2-positive gastric or gastroesophageal junction cancers feel better and live longer.

  Recruiting Phase 1 National Cancer Institute (NCI) · Houston, Texas · NCT06364410

• Comparing two drug treatments for low tumor burden follicular lymphoma

  This study is testing whether rituximab or mosunetuzumab works better for people with low tumor burden follicular lymphoma to see which treatment helps them live longer and feel better.

  Recruiting at 263 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 287 other locations · NCT06337318

• Combining venetoclax and blinatumomab with standard chemotherapy for infants with acute leukemia

  This study is testing whether adding two new treatments, venetoclax and blinatumomab, to standard chemotherapy can help infants with acute leukemia do better and stay cancer-free longer.

  Recruiting at 117 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 116 other locations · NCT06317662

• Combination treatment for older adults with FLT3 mutated acute myeloid leukemia

  This study is testing a new combination treatment for older adults with a specific type of leukemia to see if it helps them achieve better remission compared to the standard treatment.

  Recruiting at 213 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 228 other locations · NCT06317649

• Personalized treatment for advanced solid tumors using antibody-drug conjugates

  This study is testing if personalized treatments using special antibody-drug combinations can help people with advanced solid tumors that have certain proteins.

  Recruiting at 29 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 28 other locations · NCT06311214

• Combining iadademstat with immunotherapy for advanced small cell lung cancer

  This study is testing whether adding a new drug called iadademstat to standard immunotherapy can help people with advanced small cell lung cancer live longer without their disease getting worse.

  Recruiting at 33 sites Phase 1/2 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06287775

• Evaluating TAK-243 for advanced cancer treatment

  This study is testing a new drug called TAK-243 to see if it can safely help people with advanced cancer by looking at how it affects their tumors and overall health.

  Recruiting Phase 1 National Cancer Institute (NCI) · Bethesda, Maryland · NCT06223542

• Combining Nivolumab with Standard Treatment for Advanced Stomach or Esophageal Cancer

  This study is testing if adding nivolumab to the usual treatments for advanced stomach or esophageal cancer can help patients live longer and feel better.

  Recruiting at 338 sites Phase 2/3 National Cancer Institute (NCI) · Little Rock, Arkansas and 377 other locations · NCT06203600

• Using low dose tamoxifen with or without omega-3 fatty acids to reduce breast cancer risk

  This study is testing whether adding omega-3 fatty acids to low dose tamoxifen can help reduce the risk of breast cancer in overweight or obese postmenopausal women.

  Recruiting at 3 sites Phase 2 National Cancer Institute (NCI) · Kansas City, Kansas and 2 other locations · NCT06195306

• Finding the best dose of tamoxifen to reduce breast cancer risk in premenopausal women

  This study is testing if a higher dose of tamoxifen can help premenopausal women at higher risk for breast cancer by reducing breast density on mammograms.

  Recruiting at 10 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 10 other locations · NCT06184750

• Combining dinutuximab with chemotherapy and surgery for treating high-risk neuroblastoma in children

  This study is testing if adding a new medicine called dinutuximab to regular chemotherapy and surgery can help children with high-risk neuroblastoma live longer without their cancer coming back.

  Recruiting at 177 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 179 other locations · NCT06172296

• Testing neratinib alone or with palbociclib for HER2 positive solid tumors

  This study is testing if a new cancer treatment called neratinib works better alone or with another drug, palbociclib, for people with HER2 positive solid tumors, especially those with gynecologic cancers.

  Recruiting at 181 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 193 other locations · NCT06126276

• Combining blinatumomab with dasatinib or imatinib plus chemotherapy for young people with Ph+ or ABL-class Ph-like B‑ALL

  This pilot will see if adding three cycles of blinatumomab and a continuous tyrosine kinase inhibitor (dasatinib or imatinib) to a modified chemotherapy plan helps children, adolescents, and young adults with Ph+ or ABL-class Ph-like B‑ALL stay in remission longer.

  Recruiting at 159 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 160 other locations · NCT06124157

• Combining ZEN003694 with standard chemotherapy for advanced colorectal cancer

  This study is testing if a new drug called ZEN003694 can safely improve the effects of standard chemotherapy for people with advanced colorectal cancer that hasn't responded to other treatments.

  Recruiting at 10 sites Phase 1 National Cancer Institute (NCI) · Costa Mesa, California and 15 other locations · NCT06102902

• Combining chemotherapy with immunotherapy for older adults with advanced lung cancer

  This study is testing if adding chemotherapy to immunotherapy can help older adults with advanced lung cancer live longer and feel better compared to just using immunotherapy alone.

  Recruiting at 271 sites Phase 3 National Cancer Institute (NCI) · Fayetteville, Arkansas and 329 other locations · NCT06096844

• Using nivolumab with chemotherapy to treat nasopharyngeal carcinoma in young patients

  This study is testing if combining nivolumab with chemotherapy can help young patients with nasopharyngeal carcinoma live longer and feel better while reducing side effects from radiation.

  Recruiting at 84 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 85 other locations · NCT06064097

• Combining an immunotherapy drug with standard chemotherapy for advanced breast cancer

  This study is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy can help people with advanced hormone receptor-positive, HER2-negative breast cancer live longer and feel better.

  Recruiting at 552 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 564 other locations · NCT06058377

• Adding a new drug to immunotherapy for advanced nasopharyngeal cancer

  This study is testing if adding a new drug to standard immunotherapy can help people with advanced nasopharyngeal cancer live longer and feel better after their initial treatment.

  Recruiting at 83 sites Phase 2 National Cancer Institute (NCI) · Dublin, California and 94 other locations · NCT06029270

• Urolithin A supplementation for men with prostate cancer before surgery

  This study is testing if taking Urolithin A before surgery can help men with prostate cancer by reducing stress in their tumor tissue.

  Recruiting at 5 sites Phase 2 National Cancer Institute (NCI) · Los Angeles, California and 4 other locations · NCT06022822

• Combining three anti-cancer drugs for treating relapsed or refractory diffuse large B-cell lymphoma

  This study is testing a combination of three cancer drugs to see if they can help people with tough-to-treat diffuse large B-cell lymphoma feel better and respond to treatment.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 7 other locations · NCT06015880

• Using blood tests to guide immunotherapy after bladder cancer surgery

  This study is testing if blood tests can help doctors find out which bladder cancer patients need extra treatment after surgery and if combining two immunotherapy drugs works better than just one.

  Recruiting at 458 sites Phase 2/3 National Cancer Institute (NCI) · Phoenix, Arizona and 504 other locations · NCT05987241

• Testing a new vaccine to prevent HPV-related cancers in women

  This study is testing a new vaccine to see if it can safely prevent HPV-related cancers in women aged 18 to 45.

  Recruiting Phase 1 National Cancer Institute (NCI) · Madison, Wisconsin · NCT05985681

• Testing drug combinations for recurrent ovarian and endometrial cancer

  This study is testing a combination of two drugs to see if they can safely help people with recurrent ovarian and endometrial cancer by blocking tumor growth.

  Recruiting at 13 sites Phase 1 National Cancer Institute (NCI) · Augusta, Georgia and 13 other locations · NCT05950464

• Comparing acolbifene and low dose tamoxifen to prevent breast cancer in high-risk premenopausal women

  This study is testing whether acolbifene or low dose tamoxifen can help prevent breast cancer in high-risk premenopausal women.

  Recruiting at 4 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 3 other locations · NCT05941520

• Combining immunotherapy with prednisone and sirolimus for kidney transplant recipients with advanced skin cancer

  This study is testing a new treatment that combines two immunotherapy drugs with prednisone and sirolimus to see if it helps kidney transplant recipients with advanced skin cancer while keeping their transplanted kidney safe.

  Recruiting at 25 sites Phase 1/2 National Cancer Institute (NCI) · La Jolla, California and 25 other locations · NCT05896839

• Combining SNDX-5613 with standard chemotherapy for newly diagnosed acute myeloid leukemia

  This study is testing a new drug called SNDX-5613 combined with standard chemotherapy to see if it can improve treatment for people with newly diagnosed acute myeloid leukemia that has certain genetic mutations.

  Recruiting at 21 sites Phase 1 National Cancer Institute (NCI) · Orange, California and 22 other locations · NCT05886049

• Comparing two immunotherapy agents for treating a specific type of lymphoma

  This study is testing whether a new immunotherapy called mosunetuzumab works better than the standard treatment rituximab for people with a specific type of lymphoma.

  Recruiting at 34 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 36 other locations · NCT05886036

• Tovorafenib (DAY101) for relapsed or treatment‑resistant Langerhans cell histiocytosis in children and young adults

  This Phase II trial tests whether tovorafenib (DAY101) can shrink or control progressive, relapsed, or treatment‑resistant Langerhans cell histiocytosis in children and young adults.

  Recruiting at 117 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 122 other locations · NCT05828069

• Combining ZEN003694 with Capecitabine for Advanced Cancer Treatment

  This study is testing a new combination of two cancer drugs, ZEN003694 and capecitabine, to see if it can help people with advanced cancers that haven't responded to other treatments.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Irvine, California and 21 other locations · NCT05803382

• Comparing two treatments for metastatic midgut neuroendocrine tumors

  This study is testing whether a retreatment with a specific type of radiation therapy or a daily pill works better for people with advanced midgut neuroendocrine tumors who have already had radiation therapy before.

  Recruiting at 40 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 42 other locations · NCT05773274

• Testing a new combination of chemotherapy drugs for advanced sarcoma

  This study is testing a new combination of chemotherapy drugs to see if it can help people with advanced sarcoma feel better and manage their disease.

  Recruiting at 15 sites Phase 1 National Cancer Institute (NCI) · Los Angeles, California and 15 other locations · NCT05711615

• Testing CBX-12 for advanced solid cancers

  This study is testing a new drug called CBX-12 to see if it can help people with advanced solid tumors by killing cancer cells more effectively than current treatments.

  Recruiting Phase 1 National Cancer Institute (NCI) · Bethesda, Maryland · NCT05691517

• Combining Temozolomide and M1774 to Treat Advanced Cancer

  This study is testing a combination of two cancer drugs, temozolomide and M1774, to see if they can help people with advanced metastatic cancers feel better and improve their treatment outcomes.

  Recruiting at 15 sites Phase 1/2 National Cancer Institute (NCI) · Irvine, California and 22 other locations · NCT05691491

• Testing a radioactive treatment for metastatic prostate cancer with neuroendocrine cells

  This study is testing a radioactive treatment to see if it can help people with metastatic prostate cancer that has neuroendocrine features feel better and live longer.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 12 other locations · NCT05691465

• Combining two anti-cancer drugs for advanced solid tumors

  This study is testing if a combination of two anti-cancer drugs can be safely used to help people with advanced solid tumors that have spread.

  Recruiting at 6 sites Phase 1 National Cancer Institute (NCI) · Bethesda, Maryland and 6 other locations · NCT05687136

• Combining Sunitinib with Lutetium Lu 177 Dotatate for Pancreatic Neuroendocrine Tumors

  This study is testing if combining two treatments, sunitinib and lutetium Lu 177 dotatate, can help people with advanced pancreatic neuroendocrine tumors live longer and feel better.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 9 other locations · NCT05687123

• Testing novobiocin for cancer patients with DNA repair gene alterations

  This study is testing a drug called novobiocin to see if it can help cancer patients with certain gene changes in their tumors feel better and fight their cancer.

  Recruiting at 18 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 22 other locations · NCT05687110

• Comparing standard therapy to immunotherapy for early stage Hodgkin lymphoma

  This study is testing if adding immunotherapy to standard chemotherapy helps people with early stage Hodgkin lymphoma live longer and stay cancer-free.

  Recruiting at 404 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 418 other locations · NCT05675410

• ONC201 (dordaviprone) for safety and prevention of colorectal polyps in high-risk adults.

  This trial tests whether different doses of ONC201 (dordaviprone) are safe and can help prevent new colorectal polyps in adults with familial adenomatous polyposis or a history of multiple adenomas.

  Recruiting at 3 sites Phase 1 National Cancer Institute (NCI) · Ann Arbor, Michigan and 4 other locations · NCT05630794

• Screening to match myeloid cancer patients with treatment options

  This study is testing a new way to help people with acute myeloid leukemia or myelodysplastic syndrome find the right treatment options faster by checking their blood and bone marrow for specific markers.

  Recruiting at 345 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 359 other locations · NCT05564390

• Targeted therapy for advanced solid tumors based on genetic testing

  This study is testing whether matching patients with advanced solid tumors to specific treatments based on their genetic makeup can improve their outcomes when standard options have failed.

  Recruiting at 437 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 483 other locations · NCT05564377

• Testing new treatments for high-risk acute myeloid leukemia

  This study is testing new treatment combinations for people with high-risk acute myeloid leukemia to see if they can achieve better remission rates than the standard therapy.

  Recruiting at 212 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 226 other locations · NCT05554406

• Comparing different treatments for younger patients with intermediate risk acute myeloid leukemia

  This study is testing different treatment combinations for younger patients with intermediate risk acute myeloid leukemia to see which one helps them achieve better remission and has fewer side effects.

  Recruiting at 177 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 186 other locations · NCT05554393

• Adding selinexor to temozolomide for recurrent glioblastoma.

  This trial tests whether adding selinexor to standard temozolomide helps adults with IDH‑wildtype, MGMT‑methylated glioblastoma that has come back.

  Recruiting at 35 sites Phase 1/2 National Cancer Institute (NCI) · Phoenix, Arizona and 38 other locations · NCT05432804

• Combining ZEN003694 and Pembrolizumab with Standard Chemotherapy for Advanced Triple-Negative Breast Cancer

  This study is testing a new combination of a targeted drug and immunotherapy with standard chemotherapy to see if it helps people with advanced triple-negative breast cancer.

  Recruiting at 5 sites Phase 1 National Cancer Institute (NCI) · Boston, Massachusetts and 5 other locations · NCT05422794

• Combining two anti-cancer drugs for patients with advanced tumors

  This study is testing a new combination of two anti-cancer drugs to see if it can help teenagers and adults with advanced tumors feel better and improve their treatment options.

  Recruiting at 7 sites Phase 1 National Cancer Institute (NCI) · Los Angeles, California and 6 other locations · NCT05372640

• Testing a combination of two anti-cancer drugs for HER2-positive solid tumors

  This study is testing a combination of two cancer drugs to see if they can safely help people with advanced HER2-positive solid tumors.

  Recruiting at 15 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 17 other locations · NCT05372614

• Combining Atezolizumab and Selinexor for Alveolar Soft Part Sarcoma

  This study is testing if a combination of two drugs, atezolizumab and selinexor, can help shrink tumors in patients with advanced alveolar soft part sarcoma better than standard treatments.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Los Angeles, California and 12 other locations · NCT05333458

• Combining Nivolumab and ASTX727 for B-Cell Lymphoma Treatment

  This study is testing a new combination of two treatments, nivolumab and ASTX727, to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better and live longer.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 8 other locations · NCT05272384

• Combining Ipatasertib with Chemotherapy and Radiation for Head and Neck Cancer

  This study is testing if adding a new drug called ipatasertib to chemotherapy and radiation can help people with advanced head and neck cancer feel better and improve their treatment results.

  Recruiting at 13 sites Phase 1 National Cancer Institute (NCI) · Tampa, Florida and 17 other locations · NCT05172245

• Combining cabozantinib and nivolumab to treat advanced melanoma and head and neck cancer

  This study is testing a combination of two cancer drugs, cabozantinib and nivolumab, to see if they can help people with advanced melanoma or head and neck cancer while also looking at how to better match treatments to patients based on their tumor characteristics.

  Recruiting at 211 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 231 other locations · NCT05136196

• Effect of broccoli seed and sprout extract on tobacco carcinogens in heavy smokers

  This study is testing if broccoli seed and sprout extract can help heavy smokers get rid of harmful substances from tobacco in their bodies.

  Recruiting at 3 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 2 other locations · NCT05121051

• Testing nivolumab with or without ipilimumab for recurrent endometrial cancer

  This study is testing if adding ipilimumab to nivolumab can help people with recurrent endometrial cancer live longer and feel better compared to just using nivolumab alone.

  Recruiting at 122 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 137 other locations · NCT05112601

• Combining ZEN003694 and Binimetinib for Advanced Solid Tumors with RAS Alterations

  This study is testing a combination of two cancer drugs, ZEN003694 and binimetinib, to see if they can help people with advanced solid tumors that have RAS changes.

  Recruiting Phase 1 National Cancer Institute (NCI) · Boston, Massachusetts and 3 other locations · NCT05111561

• Combining immunotherapy with chemotherapy for advanced neuroendocrine cancer

  This study is testing if adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with advanced neuroendocrine cancer live longer and feel better.

  Recruiting at 243 sites Phase 2/3 National Cancer Institute (NCI) · Anchorage, Alaska and 265 other locations · NCT05058651

• Testing a new drug combination for advanced cancer and lymphoma

  This study is testing a new combination of two drugs to see if it can help people with advanced cancer and lymphoma feel better and live longer.

  Recruiting at 3 sites Phase 1/2 National Cancer Institute (NCI) · New Haven, Connecticut and 2 other locations · NCT05053971

• Testing a new anti-cancer drug combined with chemotherapy for NUT carcinoma patients

  This study tests a new anti-cancer drug combined with chemotherapy to see if it can help people with NUT carcinoma shrink their tumors and improve their treatment outcomes.

  Recruiting at 5 sites Phase 1/2 National Cancer Institute (NCI) · Los Angeles, California and 4 other locations · NCT05019716

• Combining chemotherapy and immunotherapy for peritoneal mesothelioma treatment

  This study is testing if adding a new immune treatment to standard chemotherapy can help people with peritoneal mesothelioma respond better to their treatment.

  Recruiting at 38 sites Phase 2 National Cancer Institute (NCI) · Phoenix, Arizona and 40 other locations · NCT05001880

• Combining three medications for advanced kidney cancer treatment

  This study is testing a combination of three medications to see if they can help people with advanced kidney cancer feel better and live longer.

  Recruiting at 6 sites Phase 2 National Cancer Institute (NCI) · La Jolla, California and 12 other locations · NCT04981509

• Using obeticholic acid to prevent progression in Barrett's esophagus

  This study is testing if the medication obeticholic acid can help prevent Barrett's esophagus from getting worse in people at risk of developing esophageal cancer.

  Recruiting at 6 sites Phase 2 National Cancer Institute (NCI) · Kansas City, Kansas and 7 other locations · NCT04939051

• Using Olaparib to Prevent Recurrence in Patients with Resected Pancreatic Cancer and Specific Genetic Mutations

  This study is testing if the drug olaparib can help prevent pancreatic cancer from coming back in patients who have had surgery and specific genetic mutations.

  Recruiting at 261 sites Phase 2 National Cancer Institute (NCI) · Anchorage, Alaska and 455 other locations · NCT04858334

• Comparing venetoclax and rituximab to ibrutinib and rituximab for treating Waldenstrom's macroglobulinemia

  This study is testing whether a new combination of venetoclax and rituximab works better than the standard treatment of ibrutinib and rituximab for people with Waldenstrom's macroglobulinemia who haven't been treated before.

  Recruiting at 106 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 149 other locations · NCT04840602

• Comparing an immunotherapy drug to chemotherapy and radiation for recurrent head and neck cancer after surgery

  This study is testing whether an immunotherapy drug called pembrolizumab can help people with recurrent head and neck cancer live longer compared to the usual treatment of chemotherapy and radiation.

  Recruiting at 119 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 177 other locations · NCT04671667

• Testing a radioactive drug for advanced bronchial neuroendocrine tumors

  This study is testing a new radioactive drug called lutetium Lu 177 dotatate to see if it can help people with advanced bronchial neuroendocrine tumors live longer and feel better compared to the standard treatment.

  Recruiting at 23 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 28 other locations · NCT04665739

• Combining Abemaciclib and Olaparib for Women with Recurrent Ovarian Cancer

  This study is testing if a combination of two cancer drugs, abemaciclib and olaparib, can help women with recurrent ovarian cancer feel better and fight their disease.

  Recruiting at 11 sites Phase 1 National Cancer Institute (NCI) · Phoenix, Arizona and 26 other locations · NCT04633239

• Adding durvalumab to chemotherapy before surgery for high-grade upper urinary tract cancer

  This study is testing whether adding an immunotherapy drug called durvalumab to standard chemotherapy before surgery can help people with high-grade upper urinary tract cancer do better.

  Recruiting at 151 sites Phase 2/3 National Cancer Institute (NCI) · Kingman, Arizona and 257 other locations · NCT04628767

• Trastuzumab Deruxtecan for Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  This study tests trastuzumab deruxtecan in children and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or resisted treatment to see if the drug can help shrink tumors.

  Recruiting at 21 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 31 other locations · NCT04616560

• Combining DS-8201a and Olaparib for HER2-Expressing Cancers

  This study is testing a new combination of two drugs, DS-8201a and olaparib, to see if it can help people with HER2-expressing cancers, especially those with ovarian cancer that hasn't responded to other treatments.

  Recruiting at 12 sites Phase 1 National Cancer Institute (NCI) · Phoenix, Arizona and 12 other locations · NCT04585958

• Blinatumomab versus blinatumomab plus nivolumab for first-relapse CD19+ B‑ALL

  This test sees if adding nivolumab to blinatumomab helps children and young adults (ages 1–30) with first-relapse CD19+ B‑cell acute lymphoblastic leukemia, including people with Down syndrome.

  Recruiting at 154 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 226 other locations · NCT04546399

• Combining lenalidomide with standard chemotherapy for adult T-cell leukemia-lymphoma

  This study is testing if adding lenalidomide to standard chemotherapy can help adults with T-cell leukemia-lymphoma feel better and live longer.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Atlanta, Georgia and 18 other locations · NCT04301076

• Early treatment for high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study tests if starting treatment early with venetoclax and obinutuzumab can help people newly diagnosed with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma live longer and feel better compared to waiting until symptoms show up.

  Recruiting at 299 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 632 other locations · NCT04269902

• Combining immunotherapy with chemotherapy for non-small cell lung cancer treatment

  This study is testing if adding an immunotherapy drug to standard chemotherapy can help people with early-stage non-small cell lung cancer live longer and feel better after their surgery.

  Recruiting at 629 sites Phase 3 National Cancer Institute (NCI) · Anchorage, Alaska and 1150 other locations · NCT04267848

• Combining osimertinib and bevacizumab for treating advanced EGFR-mutant lung cancer

  This study is testing if adding bevacizumab to osimertinib can help people with advanced EGFR-mutant lung cancer live longer and feel better compared to taking osimertinib alone.

  Recruiting at 328 sites Phase 3 National Cancer Institute (NCI) · Anchorage, Alaska and 603 other locations · NCT04181060

• Comparing selumetinib to standard chemotherapy for low-grade glioma

  This study is testing if a new drug called selumetinib can help people with low-grade glioma live longer without their cancer getting worse compared to the usual chemotherapy.

  Recruiting at 124 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 131 other locations · NCT04166409

• Combining durvalumab with chemotherapy for advanced solid tumors

  This study is testing if combining an immunotherapy drug called durvalumab with standard chemotherapy can help people with advanced solid tumors by improving their immune response and slowing down tumor growth.

  Recruiting Phase 2 National Cancer Institute (NCI) · Bethesda, Maryland · NCT03907475

• Combining immunotherapy and targeted therapy for rare bladder tumors

  This study is testing a new combination of treatments for people with rare bladder tumors that have spread, to see if it helps them live longer and feel better.

  Recruiting at 222 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 581 other locations · NCT03866382

• Using nivolumab to treat patients with autoimmune disorders and advanced cancer

  This study is testing if nivolumab can safely help people with autoimmune disorders who also have advanced cancer by looking at how well it works and what side effects it might cause.

  Recruiting at 40 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 51 other locations · NCT03816345

• Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia

  This trial will test whether inotuzumab ozogamicin followed by blinatumomab, with or without ponatinib, can help people with CD22-positive B-cell acute lymphoblastic leukemia who are newly diagnosed, have relapsed, or are refractory to prior therapy.

  Recruiting at 89 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 284 other locations · NCT03739814

• Combining a personalized vaccine with chemotherapy and immunotherapy for metastatic triple-negative breast cancer

  This study is testing if adding a personalized vaccine to chemotherapy and immunotherapy can help people with metastatic triple-negative breast cancer feel better and improve their treatment outcomes.

  Recruiting at 24 sites Phase 2 National Cancer Institute (NCI) · Orange, California and 29 other locations · NCT03606967

• Using osimertinib to treat lung cancer with specific genetic mutations

  This study is testing if a medication called osimertinib can help people with advanced lung cancer that has a specific genetic mutation feel better and live longer.

  Recruiting at 215 sites Phase 2 National Cancer Institute (NCI) · Anchorage, Alaska and 346 other locations · NCT03191149

• Identifying genetic variants linked to nerve damage in breast cancer patients treated with paclitaxel

  This study is trying to find out if certain genetic factors make breast cancer patients more likely to experience nerve damage after receiving the chemotherapy drug paclitaxel.

  Recruiting National Cancer Institute (NCI) · Boston, Massachusetts · NCT02610439

• Finding genetic variants in patients with heart failure undergoing breast cancer treatment

  This study is trying to find genetic changes in patients who have heart failure while being treated for breast cancer to help improve future treatments and understand their risks better.

  Recruiting National Cancer Institute (NCI) · Boston, Massachusetts · NCT02610426

• Identifying genetic variants linked to hypertension in breast cancer patients treated with bevacizumab

  This study is trying to find out if certain genetic traits make breast cancer patients more likely to develop high blood pressure while being treated with a drug called bevacizumab.

  Recruiting National Cancer Institute (NCI) · Boston, Massachusetts · NCT02610413

• Collecting and storing tissue and blood samples from cancer patients

  This study is collecting and storing blood and tissue samples from cancer patients to help researchers create better models for understanding cancer and testing new treatments.

  Recruiting at 18 sites National Cancer Institute (NCI) · Birmingham, Alabama and 139 other locations · NCT02474160

Quick answers

How many clinical trials run by National Cancer Institute (NCI) are recruiting right now?

137, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in United States (137 trials), Puerto Rico (24 trials), Canada (22 trials), Australia (6 trials), New Zealand (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 59, Phase 1: 36, Phase 3: 17, Phase 1/2: 15. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →